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Two regions of northern Spain, Gipuzkoa, and Cantabria present high annual incidence 
of listeriosis (1.86 and 1.71 cases per 100,000 inhabitants, respectively). We report that 
the high annual incidences are a consequence of infection with highly virulent Listeria 
monocytogenes isolates linked to fatal outcomes in elderly patients with cancer. In 
addition, listeriosis patients with cancer present low IL-17A/IL-6 ratios and significantly 
reduced levels of anti-GAPDH1–22 antibodies, identified as two novel biomarkers of poor 
prognosis. Analysis of these biomarkers may aid in reducing the incidence of listeriosis. 
Moreover, GAPDH1–22-activated monocyte-derived dendritic cells of listeriosis patients 
with cancer seem useful tools to prepare clinical vaccines as they produce mainly Th1 
cytokines.
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BaCKGRoUND
In Spain, increased cases of listeriosis were recorded between 2008 and 2014, with up to 1.15 cases 
per 100,000 inhabitants according to the last European summary report in 2014, signifying one of 
the highest incidences of listeriosis in Europe (1–4). Over this period, outbreaks were additionally 
documented in Austria, Portugal, Spain, and Denmark (1, 5–8). Listeriosis has only recently been 
listed as a notifiable disease in Spain since March 2015 (9), and therefore, the annual incidence may be 
even higher (1–5, 10, 11). Reduced immunocompetency of listeriosis patients was recently reported 
as a major risk factor for fatal outcomes (12). Epidemiologically specific Listeria monocytogenes 
genotypes show greater virulence, contributing to more human listeriosis cases (13, 14). Despite 
accumulating epidemiological data on listeriosis (1–14), effective immunological biomarkers are 
yet to be established that a priori appear to represent valuable tools to prepare clinical vaccines for 
patients at high risk of listeriosis, which may help to reduce the incidence of infectious disease.
The main purpose of this study was to establish the annual incidence of listeriosis in two 
northern Spain communities with voluntary reports of high numbers of listeriosis cases. We 
taBLe 1 | Listeriosis patients: clinical manifestations and treatments.
patients codea-age (y), 
period 2014–2015
Clinical manifestations type of infection Listeriosis treatment other treatments
HUD005-74 (deceased) Lung adenocarcinoma Bacteremia Ampicillin Cisplatin + holocraneal radiotherapy
HUD006-60 Multiple myeloma IgGλ Bacteremia, 
meningitis
Ampicillin + gentamicin Melphalan + radiotherapy + lenalodomide, 
velcade and dexamethasone
HUD007-30 Pregnancy, cesarean Corioamnionitis NT NT
HUD008-0 Premature neonate Meningitis Ampicillin NT
HUD009-74 None Meningitis Ampicillin Lisionopril
HUD010-90 Rhabdomyolysis Bacteremia Ampicillin NT
HUD011-54 None Bacteremia, blood 
diarrheal
Ampicillin NT
HUD012-65 Type I hepatorenal syndrome Peritonitis Ampicillin NT
HUD013-59 Hepatocarcinome Bacteriuria Ampicillin Surgery
HUMV006-76 (deceased) Prostate adenocarcinoma Bacteremia ND Taxocel
HUMV007-51 Squamous cell glottis carcinoma Bacteremia Amoxicillin + clavulanic + ampicillin Radiotherapy + cetuximab
HUMV009-54 Lung and bladder carcinoma Bacteremia Levofloxacin Cisplatin-etoposide
HUMV010-57 Glomerulonephritis Sepsis Meropenem + ampicillin Mycophenolate mofetil + everolimus
HUMV012-84 Cutaneous lupus Bacteremia Amoxicillin + clavulanic + ampicillin Prednisone
HUMV013-71 Glioblastoma multiforme Bacteremia Augmentin Temozolamide + radiotherapy
patients code-age (y) 
selection in 2012–2014b
Clinical manifestations type of infection Listeriosis treatment other treatments
HUD001-57 Squamous cell glottis carcinoma Bacteremia Ampicillin Cisplatin
HUD002-36 Splenectomized 
autoimmune-hypertiroidism
Bacteremia Ampicillin Tirodril
HUD003-30 Pregnancy Bacteremia NT NT
HUD004-32 Pregnancy, cesarean-2nd twin lost Bacteremia NT NT
HUMV001-89 Arteritis of giant cells Acute 
meningoencephalitis
Ampicillin Prednisone
HUMV002-65 Hepatocellular carcinoma Bacteremia Ampicillin Ablation by microwaves
HUMV003-60 Guillain–Barre syndrome, 
sarcoidosis
Bacteremia, hepatic 
abscess
Ampicillin + gentamicin Prednisone
HUMV004-56 Cirrhosis-hepatic transplant Brain abscess Ampicillin Prednisone + mycophenolate 
mofetil + tacrolimus
HUMV005-49 Cutaneous primary lymphoma of 
giant cells
Bacteremia Ampicillin + gentamicin Rituximab + local radiotherapy
aClinical manifestations and treatments of listeriosis patients during August 2014–September 2015 or in a bselection of patients in 2012–2014. Patients identified by internal codes. 
HUD, Hospital Universitario de Donostia (Gipuzcoa); HUMV, Hospital Universitario Marqués de Valdecilla (Santander, Cantabria). Age of the patient in years (y). NT, no treatment.
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further explored potential immunological and epidemiological 
biomarkers that may serve as major risk factors of fatal out-
comes as well as tools to generate clinical vaccines for patients 
at high risk of listeriosis.
study Description
Two northern Spain regions, Gipuzkoa in the Basque country 
(~700,000 inhabitants) and Cantabria (~350,000 inhabitants), 
were selected to calculate annual incidence, since these com-
munities have voluntarily reported a high number of listeriosis 
cases since 2008 (1, 4, 5, 10, 11). We compiled data on genetic 
epidemiology, clinical manifestations, virulence of clinical iso-
lates, and immunological parameters in listeriosis patients over 
the period of a year (August 2014–September 2015). This time 
period was selected to ensure that at least 5 months had passed 
after the January 2013–February 2014 outbreak (5), thus avoid-
ing inclusion of any listeriosis cases from this epidemic in our 
annual study of incidence. Non-maternal/neonatal patients who 
met the laboratory criteria or mothers with laboratory-confirmed 
listeriosis infection in the fetus, stillborn, or newborn, according 
to the Commission Decision of 28/IV/2008, were classified as 
listeriosis cases (15). In total, nine human listeriosis episodes 
were detected in Gipuzkoa and six in Cantabria, being the annual 
incidences very high, 1.86 and 1.71 cases per 100.000 inhabitants, 
respectively. Bacteria were recovered from blood in all except 
three cases, where recovery was from ascitic fluid, stool, or urine. 
Seven cases (46.7%) were adults 45–65 years of age, and six (40%) 
involved the elderly (>70 years). Seven patients presented solid- or 
blood-related tumors under chemotherapeutic treatment (50%), 
including two deceased cases, lung adenocarcinoma, squamous 
cell glottis carcinoma, lung and bladder carcinoma, glioblastoma 
multiforme, hepatocarcinoma, and multiple myeloma IgGλ. 
Two episodes (13.3%) corresponded to autoimmune diseases, 
glomerulonephritis, and cutaneous lupus, two occurred dur-
ing pregnancy, including the child of a patient infected with 
meningitis (13.3%), two episodes of meningitis or bacteremia 
were associated with elderly patients (13.3%), one case related 
to a combined liver–kidney transplantation (6.6%), and one case 
of sporadic listeriosis occurred in an apparent non-risk patient 
(6.6%) (Table 1, 2014–2015).
taBLe 2 | Listeriosis patients: microbiological and epidemiological parameters.
patients codea-age (y)c, period 2014–2015 serotyped Lineaged sequence type (st)f HUD/HUMV distributione (%) pasteur distributione (%)
HUD005-74b (deceased) 1/2a II 37 (CC37) 7.69 0.53
HUD006-60b 4b I 219 (CC4) 15.38 0.13
HUD007-30 4b I 1 (CC1) 53.84 10.27
HUD008-0 4b I 1 (CC1) 53.84 10.27
HUD009-74 4b I 219 (CC4) 15.38 0.13
HUD010-90 4b I 1 (CC1) 53.84 10.27
HUD011-54 4b I 1 (CC1) 53.84 10.27
HUD012-65 4b I 1 (CC1) 53.84 10.27
HUD013-59b 4b I 1 (CC1) 53.84 10.27
HUMV006-76b (deceased) 4b I 213 (CC213) 9.09 0.03
HUMV007-51b 4b I 6 (CC6) 9.09 1.69
HUMV009-54b 1/2b I 87 (CC87) 9.09 0.69
HUMV010-57 1/2a II 391 (CC89) 9.09 0.28
HUMV012-84 4b I 1 (CC1) 18.18 10.27
HUMV013-71b 1/2a II 26 (CC26) 9.09 0.38
patients codea-age (y)c, selection in 2012–2014h serotyped Lineaged sequence type (st)f HUD/HUMV distribution (%)e pasteur distribution (%)g
HUD001-57b 4b I 4 (CC4) NA 2.50
HUD002-36 1/2b I 87 (CC87) NA 0.69
HUD003-30 1/2b I 87 (CC87) NA 0.69
HUD004-32 4b I 1 (CC1) NA 10.27
HUMV001-89 4b I 2 (CC2) NA 6.67
HUMV002-65b 1/2b I 3 (CC3) NA 7.92
HUMV003-60 4b I 54 (CC54) NA 0.22
HUMV004-56 4b I 666 (CC666) NA 0.06
HUMV005-49b 4b I 1 (CC1) NA 10.27
aList of listeriosis patients with tumors during August 2014–September 2015 and in the selection 2012–2014. Patients identified by internal codes as in table 1.
bPatients with cancer.
cAge of patient in years (y).
dDistribution of ST per institution, expressed as a percentage.
eSerotypes and lineages of clinical bacterial isolates measured via PCR multiplex.
fSequence type, ST, of clinical bacterial isolates measured using MLST and complex clones in parentheses in the period 2014–2015 (14).
gDistribution of ST obtained from Institut Pasteur website as of October 2016, expressed as a percentage (n = 3165).
hSelection of listeriosis patients over January 2012–July 2014 based on the predominant clinical manifestations (see table 1). NA, not applied.
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Microbiological Characterization of 
Invasive L. monocytogenes
We collected invasive L. monocytogenes from 15 clinical isolates 
and serotyped the strains by agglutination (Listeria-O-antisera, 
Difco) and performed multilocus sequence typing (MLST) 
to establish L. monocytogenes sequence types (STs) using the 
primers and conditions described on the Pasteur Institute web 
page (http://bigsdb.pasteur.fr/listeria/listeria.html) (16–18). 
In total, 74% (11/15) invasive L. monocytogenes were classified 
as serotype 4b, 7% (1/15) as serotype 1/2b, and 23% (3/15) as 
serotype 1/2a, with 12 and 3 clinical isolates of lineages I and II, 
respectively. MLST genotyping revealed the following distribu-
tion: 43% ST1, 14% ST219, and 7% each of ST6, ST26, ST37, 
ST87, ST213, and ST391 genotypes. These distributions differ 
from those registered on Pasteur Institute database (columne 
in Table 2), something attributable to the limited number of 
samples. The ST87 ST of the Gipuzkoa outbreak in 2014 (5) 
was detected in Cantabria as well as other regions in northern 
Spain (10). The most prevalent ST in our clinical isolates of 
invasive L. monocytogenes was ST1, consistent with previous 
reports (10, 13, 14, 17, 18), followed by ST219. With the aid 
of M. Lecuit and M. Maury (Institut Pasteur, Paris, France), 
we assigned the corresponding clonal complexes (CC) to 
these STs. The most prevalent CC were the hypervirulent 
clones CC1 (ST1) and CC4 (ST219) (columne in Table 2). In 
agreement with data obtained from the detailed investigation 
performed in France (14), CC1 and CC4 hypervirulent clones 
corresponded to listeriosis cases of meningitis or materno-fetal 
transmission. We additionally detected another hypervirulent 
clone, ST6 (CC6), isolated from a patient with squamous cell 
glottis carcinoma (Tables 1 and 2, 2014–2015). The data col-
lectively suggest that bacterial isolates of our listeriosis patients 
have a highly virulent phenotype.
In Vitro and In Vivo Replication of Clinical 
L. monocytogenes Isolates
The in vitro replication of invasive L. monocytogenes isolates was 
assayed in human monocyte-derived dendritic cells (MoDC) 
(Methods in Supplementary Material) (19) infected at a MOI 
of 20:1 (bacteria:cells) and calculated as replication index (RI) 
as reported (20–22). This parameter is considered an indica-
tor of bacterial growth in dendritic cells (DC) comparable 
to in  vivo virulence in spleen after 72-h post-infection with 
L. monocytogenes (20, 21). Notably, L. monocytogenes isolates of 
patients with tumors presented a 1000-fold higher growth ratio 
in MoDC (asterisks and black bars in Figure  1A, 2014–2015) 
FIGURe 1 | Virulence of clinical isolates of listeriosis patients and immunological biomarkers. (a) Left panel shows the replication index of L. 
monocytogenes isolates measured as RI in MoDC (black bars). Results are expressed as the mean ± SD of triplicates. *P ≤ 0.05; **P ≤ 0.01, right panel shows the 
CFU recovered in the spleens of mice. Results are expressed as the mean ± SD of triplicates. *P ≤ 0.05. Asterisks under the bars indicate 1000-fold higher 
replication indexes than standard Listeria strains. Standard-1 corresponds to 10403S strain and standard-2 to EGD strain. †Symbols under the bars correspond to 
deceased patients. (B) IL-7A levels (pg/ml) in sera of all patients with listeriosis (2014–2015 and 2012–2014) clustered by three main clinical manifestations (tumors, 
pregnancy, and autoimmune disease) measured via flow cytometry (Methods in Supplementary Material). *P ≤ 0.05; **P ≤ 0.01. Controls are healthy donors. 
Results are expressed as the mean ± SD.
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than two standardized L. monocytogenes controls (14, 17, 20, 23). 
The highest invasive L. monocytogenes virulence corresponded 
to that in deceased patients (†, Figure 1A, left plot). We addi-
tionally examined in vivo virulence using standard procedures 
to measure the number of viable bacteria (CFU) that reached 
the spleens in C57BL/6 mice, a mice model highly resistant to 
listeriosis (20, 21, 23). Inoculation of mice with bacterial isolates 
from listeriosis patients with tumors, including those of deceased 
patients, induced 1000-fold higher levels of viable bacteria 
(CFU) in spleen, relative to those inoculated with isolates from 
the remaining listeriosis patients or either of the two standards, 
suggestive of very high virulence (right plot, Figure  1A). The 
similar in  vitro and in  vivo data suggest that measurement of 
listeriosis virulence in MoDC could provide a valid, low-cost, 
and rapid method without the necessity of inoculating mice. 
MLST genotyping of these highly virulent clinical isolates of 
listeriosis patients with tumors under active chemotherapeutic 
treatment [ST37 (CC37), ST219 (CC4), ST213 (CC213), ST6 
(CC6), ST87 (CC87), and ST26 (CC26)] revealed the presence of 
at least two hypervirulent complex clones previously reported in 
France, CC4 and CC6 (14), which, in our study, corresponded to 
those in tumor patients subjected to chemotherapeutic regimens 
of cisplatin-etoposide (CC4) and cetuximab (CC6) (Tables  1 
and 2). The genotype of the 2014 outbreak strain in northern 
Spain, ST87 (CC87), was isolated from a listeriosis patient with 
tumors subjected to chemotherapy with cisplatin-etoposide, 
confirming our previous suggestion that CC87 is a hypervirulent 
complex clone (5). Two other strains of particular interest were 
ST37 (CC37) and ST213 (CC213), isolated these strains from 
deceased patients with tumors under chemotherapy treatment 
with cisplatin and taxocel. These strains displayed the highest 
virulence and emerged as novel hypervirulent strains associated 
with listeriosis patients containing tumors. We concluded that 
patients with tumors treated with chemotherapy present a high-
risk factor for invasive L. monocytogenes infection, consistent 
with earlier reports (12), since this patient population is highly 
sensitive to previously reported hypervirulent strains, such as 
CC4, CC6 (17), or CC87 (5), and newly emerging hypervirulent 
complex clones, CC37 or CC213, that may cause fatal outcomes 
(this study).
taBLe 3 | Blood parameters of listeriosis patients: patients with tumors.
patients codea-ageb, 
period 2014–2015
Blood testc (%) Cytokinesd and antibodiese in sera
pMN (42–75) Lymph (20–51) Mo (1–13) IL-17a/IL-6 IFN-γ IL-6 IL-10 anti-GapDH1–22
HUD005-74 (died) 92# 4.9 2.1 1.20 ± 0.1** 4.7 ± 0.1 9.4 ± 0.4 4.9 ± 0.2 0.02 ± 0.1
HUD006-60 87 5.8 6.6 1.20 ± 0.2** 4.5 ± 0.1 10.2 ± 0.1 5.1 ± 0.3 0.38 ± 0.2**
HUD013-59 82.5 6.0 11.1 1.10 ± 0.1 4.0 ± 0.1 10.9 ± 0.2 5.3 ± 0.2 0.31 ± 0.2**
HUMV006-76 (died) 55# 9.0 5.0 1.75 ± 0.1 4.4 ± 0.2 6.6 ± 0.2 4.1 ± 0.2 0.05 ± 0.1
HUMV007-51 84# 5.0 10.2 2.80 ± 0.1* 2.2 ± 0.1 5.1 ± 0.2 1.6 ± 0.1 0.5 ± 0.2*
HUMV009-54 95 3.0 1.1 2.80 ± 0.2 1.4 ± 0.2 6.0 ± 0.1 4.6 ± 0.1 0.7 ± 0.2**
HUMV013-59 89 5.2 4.7 1.20 ± 0.1** 0.8 ± 0.1 9.0 ± 0.5 3.8 ± 0.1 0.2 ± 0.1**
CoNtRoL-52 45           43 11 4.83 ± 0.2 2.4 ± 0.2 3.1 ± 0.2 2.4 ± 0.1 0.16 ± 0.1
patients code-age, 
selection in 2012–2014f
Blood test (%) Cytokines and antibodies in sera
pMN (42–75) Lymph (20–51) Mo (1–13) IL-17a/IL-6 IFN-γ IL-6 IL-10 anti-GapDH1–22
HUD001-57 76# 14 8 3.25 ± 0.1** 4.6 ± 0.2 8.0 ± 0.4 4.0 ± 0.1 1.14 ± 0.1**
HUMV002-65 90 22 4 0.95 ± 0.1 2.1 ± 0.1 19 ± 0.9 2.4 ± 0.1 0.80 ± 0.2*
HUMV005-49 87# 5 8 1.59 ± 0.2** 2.6 ± 0.1 7.9 ± 0.3 4.0 ± 0.1 0.50 ± 0.1**
CoNtRoL-51 42 46 12 4.83 ± 0.2 2.3 ± 0.2 3 ± 0.2 2.3 ± 0.1 0.15 ± 0.1
aListeriosis patients with tumors from August 2014 to September 2015 (asterisks) and patients with other clinical manifestations (miscarriage, renal transplant, and autoimmune as 
controls of parameters in other patients). Patients were identified by internal codes as in table 1.
bAge of patient in years.
cBlood tests correspond to routine assays indicating the percentages of neutrophils (PMN), lymphocytes (Lymph), and monocytes (MO). Controls are healthy donors. Values in 
parentheses refer to ranges of normal values.
#Patients with immature granulocytes.
dCytokine concentration in sera (pg/ml) and IL-17A/IL-6 ratios expressed as the mean of ratio units (U) of triplicates ± SD. **P ≤ 0.01; *P ≤ 0.05.
eSera of listeriosis patients were examined for peptide-ELISA (anti-GAPDH1–22) (21, 30). Results are presented as optical units (OD) and mean values ± SD of triplicate experiments. 
**P ≤ 0.01; *P ≤ 0.05.
fSelected listeriosis patients with malignancies in 2012–2014.
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Listeriosis Biomarkers of poor prognosis
Since a major risk for invasive L. monocytogenes infection in our 
patients is reduced immunocompetency, it is possible that specific 
immunological parameters contribute more significantly as risk 
factors. Two parameters appear relevant for the immune status 
of invasive L. monocytogenes-infected individuals. First, the Th1/
Th17-Th2 cytokine balance (24–27) is a determinant of bacterial 
dissemination success, especially in elderly populations with 
diminished Th17 responses (28). Second, the levels of antibodies 
against the L. monocytogenes GAPDH virulence factor epitope, 
GAPDH1–22, are relevant biomarkers. Anti-GAPDH1–22 antibody 
titers reflect the ability of GAPDH to confer listeriosis protection 
(20, 21, 29, 30). Blood tests of listeriosis patients reflected the 
expected parameters: low lymphocyte numbers (3%–6%), normal 
monocyte values (2%–13%) (Table 3, blood test columns), and 
high neutrophil counts in several patients (≥ 75%–94.9%), with 
immature granulocytes in certain patients (28.5%), and especially 
high numbers in the two deceased patients. Patients with tumors, 
in particular deceased patients, presented very low IL-17A/IL-6 
ratios and high levels of IL-6 and IL-10 in sera, while IFN-γ 
levels were similar as controls (Table 3, 2014–2015; Figure 1B). 
However, listeriosis patients with autoimmune diseases or mis-
carriages showed high levels of IL-17A/IL-6 ratios (Table S1 in 
Supplementary Material). These results indicate that impairment 
of the Th17/Th2 balance toward Th2 responses may present a risk 
factor leading to fatal outcomes.
High levels of IgG antibodies (OD ≥ 2.0) against the bacterial 
epitope, GAPDH1–22 (20, 21), were detected in listeriosis patients 
with miscarriages, autoimmune diseases, or kidney transplants 
(OD of 2.5–4.5 OD) (Table S1 in Supplementary Material). The 
majority of listeriosis patients containing tumors had low IgG 
anti-GAPDH1–22 levels (OD of 0.2–0.8), presenting the deceased 
patients basal levels (0.02–0.05 OD) (Table 3, anti-GAPDH1–22 
column). Anti-listeriolysin O (LLO) antibodies were detected 
at extremely low levels in all listeriosis patients (≤0.15 OD), 
eliminating the possibility of using LLO antibodies as biomark-
ers (data not shown). Accordingly, we conclude that low levels 
of anti-GAPDH1–22 antibodies, together with low IL-17A levels, 
are two valid immunological biomarkers of poor prognosis 
in listeriosis patients with tumors under chemotherapeutic 
treatment.
Next, we selected representative listeriosis patients between 
2012 and 2014 from our institutional biobanks containing stores 
of bacterial isolates and cells to establish the epidemiological 
and immunological parameters of interest. In total, 81 cases of 
listeriosis between 2012 and 2014 occurred, including 16 deaths, 
9 with tumors, 2 autoimmune diseases, 1 cirrhosis, 2 fetuses 
(miscarriages), and 1 child (stillbirth). Our selection of listeriosis 
patients was based on those representative of the most prevalent 
clinical manifestations in our institutions, specifically, those with 
tumors, autoimmune disease, miscarriages, and renal or hepatic 
transplants (5, 4, 11). Consequently, we selected three listeriosis 
patients with tumors, squamous cell glottis carcinoma treated 
with cisplatin, hepatocellular carcinoma treated with microwave 
ablation, and cutaneous primary lymphoma of giant cells sub-
jected to rituximab treatment; three listeriosis patients with auto-
immune diseases, an autoimmune hyperthyroidism treated with 
tirodril, arteritis of giant cells, and a Guillain–Barre syndrome 
FIGURe 2 | activation of MoDC from listeriosis patients with cancer. (a) Differentiated and GAPDH1–22-activated MoDC from listeriosis patients with tumors 
(Methods in Supplementary Material) were examine for cell surface expression. Results are expressed as the percentages of positive cells ± SD. *P ≤ 0.05; 
**P ≤ 0.01. (B) Cytokine concentration in supernatants of GAPDH1–22-activated MoDC. Results are expressed as the mean of cytokine concentrations (pg/ml) ±SD 
and ANOVA was applied. *P ≤ 0.05; **P ≤ 0.01.
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treated with prednisone, two listeriosis-associated miscarriages 
in pregnant women, and one listeriosis patient with cirrhosis 
and hepatic transplant treated with several immune-suppressors 
(prednisone, mycophenolate mofetil, and tacrolimus) (Table 1, 
selection in 2012–2014 rows). We confirmed the isolation of 
highly virulent clinical isolates as CC1, CC3, and CC4 from listeri-
osis patients with tumors subjected to chemotherapy. Verification 
of virulence in vitro using MoDC or in vivo revealed 1000-fold 
higher RI values and CFU than the standard bacteria (Table 2, 
selection in 2012–2014 rows; Figure 1A, asterisks under selection 
2012–2014). Second, we detected in the listeriosis patients with 
cancer, low levels of IL-17A (bars with asterisk in Figure  1B; 
Table  3, selection in 2012–2014 rows) and anti-GAPDH1–22 
antibody levels (anti-GAPDH1–22 column in Table  3, selection 
2012–2014). All other listeriosis groups of patients (autoimmune, 
hepatic transplanted, or miscarriages) presented bacterial isolates 
with virulence similar to standard strains (Figure 1A, selection 
2012–2014) as well as high IL-17A and IgG anti-GAPDH1–22 
levels (Table  3; Table S1 in Supplementary Material, selection 
2012–2014).
Since the main risk factors in our listeriosis patients with 
tumors subjected to chemotherapeutic treatments were identi-
fied as reduced Th17 immunocompetency, we hypothesized 
that this biomarker parameter could be improved in activated 
MoDC. We based our hypothesis in the ability of DC to elicit 
pro-inflammatory Th1/Th17 and effective B cell-CD4+ T cell 
immune responses (21, 26, 27), even in clinical trials for patients 
with cancer (31). For this purpose, we activated MoDC from all 
listeriosis patients with cancer vaccine with GAPDH1–22 peptide 
as described (20, 21) and observed in all MoDC an activated 
phenotype, CD45+MHC-II+CD86+CD14−, similar to activated 
MoDC from controls (19–21) (Figure  2A). We also observed 
that GAPDH1–22-activated MoDC from listeriosis patients with 
cancer released high levels of TNF-α while low levels of IL-6 
and IL-10 (Figure 2B), suggesting a shifting toward Th1 pattern. 
Finally, we have not addressed here the type of food associated 
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with our listeriosis patients but in all cases, listeriosis infection 
was related to consumption of contaminated food as reported in 
other epidemiological studies (1–14, 17).
DIsCUssIoN
Epidemiological studies of European outbreaks and case studies, 
coordinating clinical data and bacteriological genotyping, have 
led to significant progress in listeriosis surveillance and recently 
revealed the presence of hypervirulent strains in clinical isolates 
(5–14, 16–18) as well as reduced immunocompetency as a main 
risk factor (12). Our data on listeriosis cases collected from two 
northern Spain communities, Gipuzkoa and Cantabria, over 
the course of a year (obtained to calculate annual listeriosis 
incidences) were in agreement with these findings. Our study 
concludes that the most important risk factors for listeriosis are 
the reduced Th17 immune competency of patients with cancer 
associated with the chemotherapy received and their high sensi-
tivity to infection with hypervirulent strains, along with low levels 
of two immunological biomarkers, IL-17A/IL-6 ratios, and IgG 
anti-GAPDH1–22 antibodies.
First, fatal outcomes were only observed in listeriosis patients 
with cancer receiving chemotherapy and not in autoimmune 
or renal-hepatic transplanted patients receiving immune-
suppressants or in the elderly, arguing low Th17 immune abilities 
caused by chemotherapy were risk factors more important than 
immune-senescence or autoimmunity.
Second, we presented a simple and rapid method to exam-
ine virulence in resting MoDC that revealed a correlation of 
L. monocytogenes hypervirulent strains with mortality in listeri-
osis patients with tumors receiving chemotherapy. In particular, 
these patients display high sensitivity not only to infections with 
hypervirulent invasive L. monocytogenes strains associated with 
meningitis, such as CC1, CC4, or CC6 (14) and other hyperviru-
lent bacterial strains prevalent in northern Spain communities, 
such as CC87 (5, 10), but also to newly reported hypervirulent 
invasive L. monocytogenes strains, such as CC37, CC26, and 
CC213, isolated from deceased patients (this study). Third, two 
biomarkers in the sera of patients with poor listeriosis prognosis 
were distinguished: (i) low IL-17A/IL-6 ratios that reflected a shift 
in the immune balance toward Th2 anti-inflammatory responses 
and (ii) low production of anti-GAPDH1–22 antibodies that 
suggested reduced CD4+ T cell–B cell responses. Dysfunction 
of Th17 immune responses in listeriosis patients with tumors 
under chemotherapeutic treatment appears to explain the high 
bacterial loads and reduced production of antibodies (24, 28), as 
IgG anti-GAPDH1–22 antibodies. Listeriosis patients with other 
co-morbidities presented better Th17 and CD4+ T cell immune 
responses. High levels of IL-6 were also reported in bacterial 
meningitis of children and experimental listeriosis (32, 33), 
suggesting this cytokine plays a relevant role. Moreover, IL-10 
high levels were also reported to increase in listeriosis of aged 
mice with high bacterial loads (28). Therefore, high levels of Th2 
cytokines (IL-6 or IL-10) seemed related with severe listeriosis.
Vaccinations are best measures to prevent opportunistic 
infections, such as invasive L. monocytogenes. In this regard, 
DC or synthetic vaccines containing GADPH1–22 epitopes and 
targeted to DC seemed to confer protection against experimental 
listeriosis, promoting Th1-Th17 and CD4+-CD8+ T cell immune 
responses (20, 21, 30, 34). Here, we report that GAPDH1–22 
epitopes can activate MoDC of listeriosis patients with cancer 
receiving chemotherapy to release high levels TNF-α while low 
production of IL-6 and IL-10, a clear Th1 cytokine pattern. These 
findings should contribute toward meeting the urgent need to 
develop clinical MoDC vaccines for improving Th17 immune 
competency in listeriosis patients with cancer.
CoNCLUsIoN
Listeriosis is a serious infection that causes mortality especially in 
fetuses and elderly patients with tumors under chemotherapeutic 
treatment. Examined annual incidences of listeriosis in Gipuzkoa 
and Cantabria indicated 1.86 and 1.71 cases per 100,000 inhabit-
ants. Considering the reduced Th17 immunocompetency as the 
main risk factor of listeriosis, biomarkers of poor prognosis, 
such as high sensitivity to hypervirulent Listeria clones, low 
IL-17A/IL-6 ratios, and anti-GAPDH1–22 antibodies should assist 
in reducing listeriosis incidence. They can also contribute to 
listeriosis epidemiology and select vaccine antigens and vectors 
that improve innate and specific immune abilities of patients at 
high risk of listeriosis.
statistics
For all laboratory analyses, in vitro and in vivo virulence assays, 
blood tests and antibodies assays via ELISA, a Student’s t-test was 
applied. All analyses were performed in triplicate, and results 
expressed as the mean ± SD calculated. P ≤ 0.05 was considered 
significant. The GraphPad software was used for graph genera-
tion. ANOVA was applied for cytokine measurements according 
to the manufacturer’s instructions.
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protocol (permit number: 2012/06) that followed Spanish legisla-
tion (RD 1201/2005). Surgeries were performed under sodium 
pentobarbital anesthesia, and all efforts were made to minimize 
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